Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat
Status:
Terminated
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to treat metastatic melanoma with a combination of standard
chemotherapy (decitabine and Temozolomide in a dose escalation scheme) with an study drug
called panobinostat. This combination is proposed to unlock genes that may contribute to
mechanisms that cause tumor growth.
The primary objectives of this study are:
- To evaluate the safety and tolerability of the proposed schedule of decitabine,
temozolomide and panobinostat in the treatment of metastatic melanoma.
- To define any Dose Limiting Toxicity (DLT) and maximum tolerated dose (MTD) of the
combination of decitabine, temozolomide and panobinostat.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Iowa
Collaborators:
Holden Comprehensive Cancer Center Novartis Pharmaceuticals